Liraglutide (Saxenda), tirzepatide (Zepbound), and semaglutide (Wegovy) are FDA-approved for long-term use
In recent years, the food and pharmaceutical industries have increasingly favored the use of natural products over synthetic compounds, based on the assumption that synthetic agents are inherently more toxic
Patients often experience nausea, vomiting, diarrhea, constipation, and abdominal pain, especially when first starting the medication or increasing the dose
Maternal hypothyroidism has been associated with increased risk for preeclampsia, miscarriage, stillbirth, preterm birth, and low-birth-weight infants (reviewed in 12)
Aetna typically approves Wegovy and Zepbound PAs for 12 months at a time